These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25899862)

  • 21. The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia.
    DeAngelo DJ
    Hematology Am Soc Hematol Educ Program; 2015; 2015():400-5. PubMed ID: 26637749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
    Brower V
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
    [No Abstract]   [Full Text] [Related]  

  • 24. CAR T-cells merge into the fast lane of cancer care.
    Frey NV; Porter DL
    Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies.
    O'Dwyer KM; Liesveld JL
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):184-192. PubMed ID: 29050691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
    Watkins MP; Bartlett NL
    Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances of treatment study on acute lymphoblastic leukemia with chimeric antigen receptor modified T cells].
    Weng WW; Tang YM
    Zhonghua Er Ke Za Zhi; 2019 Aug; 57(8):643-646. PubMed ID: 31352754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
    Imai C; Mihara K; Andreansky M; Nicholson IC; Pui CH; Geiger TL; Campana D
    Leukemia; 2004 Apr; 18(4):676-84. PubMed ID: 14961035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies in acute lymphoblastic leukemia.
    Jabbour E; O'Brien S; Ravandi F; Kantarjian H
    Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunotherapies in lymphoid malignancies.
    Batlevi CL; Matsuki E; Brentjens RJ; Younes A
    Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy.
    Wang J; Hu Y; Huang H
    J Leukoc Biol; 2017 Dec; 102(6):1347-1356. PubMed ID: 29018147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
    Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
    Maino E; Bonifacio M; Scattolin AM; Bassan R
    Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR therapy: the CD19 paradigm.
    Sadelain M
    J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.